Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19
Open Access
- 16 February 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (7), 644-645
- https://doi.org/10.1001/jama.2021.0585
Abstract
In this issue of JAMA, Gottlieb et al report the findings of the ongoing BLAZE-1 (Blocking Viral Attachment and Cell Entry with SARS-CoV-2 Neutralizing AntibodiThis publication has 4 references indexed in Scilit:
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- Genetic Variants of SARS-CoV-2—What Do They Mean?JAMA, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19The New England Journal of Medicine, 2021
- The Challenges Ahead With Monoclonal AntibodiesJAMA, 2020